Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Theriva Biologics Inc. (TOVX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: TOVX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7
1 Year Target Price $7
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -59.28% | Avg. Invested days 13 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.14M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Price to earnings Ratio - | 1Y Target Price 7 | ||
Volume (30-day avg) 2 | Beta 0.66 | 52 Weeks Range 0.37 - 2.64 | Updated Date 10/17/2025 |
52 Weeks Range 0.37 - 2.64 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.22 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -42.17% | Return on Equity (TTM) -154.45% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -5332232 | Price to Sales(TTM) - |
Enterprise Value -5332232 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.72 | Shares Outstanding 9597952 | Shares Floating 9584803 |
Shares Outstanding 9597952 | Shares Floating 9584803 | ||
Percent Insiders 0.14 | Percent Institutions 8.1 |
Upturn AI SWOT
Theriva Biologics Inc.
Company Overview
History and Background
Theriva Biologics, Inc. (formerly Synthetic Biologics, Inc.) is a clinical-stage biopharmaceutical company focused on developing new therapies to treat diseases associated with bacteria. Founded as Synthetic Biologics, the company rebranded to Theriva Biologics in 2023, reflecting a shift in its therapeutic focus.
Core Business Areas
- VCN-01: An oncolytic adenovirus designed to selectively replicate in tumors with the aim of improving cancer treatment outcomes.
- SYN-004 (ribaxamase): Designed to degrade certain intravenous beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent Clostridioides difficile infection (CDI), antimicrobial resistance (AMR), and microbiome disruption.
Leadership and Structure
Steven A. Shallcross is the Chief Executive Officer. The company has a board of directors responsible for overseeing its strategic direction. Details on the full organizational structure can be found in their SEC filings.
Top Products and Market Share
Key Offerings
- VCN-01: An oncolytic adenovirus undergoing clinical trials for the treatment of various cancers, including pancreatic cancer. Currently in development, market share data is not applicable. Competitors include companies developing other oncolytic viruses or cancer therapies such as Amgen (T-VEC), Oncolytics Biotech, and Replimune.
- SYN-004 (ribaxamase): A potential therapy to prevent antibiotic-associated complications by degrading certain IV beta-lactam antibiotics in the GI tract. Currently in development, market share data is not applicable. Competitors include companies developing microbiome-protecting therapies and CDI treatments such as Seres Therapeutics and Vedanta Biosciences.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. Focus areas include oncology, infectious diseases, and microbiome-related therapies.
Positioning
Theriva Biologics is a clinical-stage company focusing on unmet medical needs in oncology and infectious diseases. Their competitive advantage lies in their novel therapeutic approaches, particularly VCN-01's tumor selectivity and ribaxamase's potential to protect the gut microbiome.
Total Addressable Market (TAM)
The TAM for cancer therapies is substantial, exceeding $200 billion globally. The TAM for therapies targeting antibiotic-associated complications is also significant, estimated in the billions of dollars. Theriva's VCN-01 aims to address a portion of the pancreatic cancer market and other solid tumors and ribaxamase targets a share of the antibiotic-associated complications, including CDI.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approaches (VCN-01, ribaxamase)
- Focus on unmet medical needs
- Experienced management team
Weaknesses
- Clinical-stage company with no marketed products
- Reliance on clinical trial success
- Limited financial resources
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Difficulty in raising capital
Competitors and Market Share
Key Competitors
- AMGN
- MRTX
- BNTX
Competitive Landscape
Theriva Biologics faces significant competition from established pharmaceutical companies and other biotech firms. Their competitive advantage rests on the potential efficacy and safety of their novel therapies.
Growth Trajectory and Initiatives
Historical Growth: As a clinical-stage company, historical growth is primarily related to advancing its pipeline through clinical trials.
Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and potential commercialization or partnering of their assets. Analyst estimates are variable and dependent on clinical trial outcomes.
Recent Initiatives: Recent initiatives include advancing VCN-01 and SYN-004 through clinical trials and exploring partnerships.
Summary
Theriva Biologics is a clinical-stage biopharmaceutical company with promising novel therapies in development. Its success is heavily dependent on positive clinical trial results and the ability to secure funding. The company faces significant competition and regulatory hurdles, requiring strategic execution and effective partnerships to realize its potential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings (10-K, 10-Q), Company Website, Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual due diligence and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Theriva Biologics Inc.
Exchange NYSE MKT | Headquaters Rockville, MD, United States | ||
IPO Launch date 2006-12-18 | CEO, CFO, Treasurer, Corporate Secretary & Director Mr. Steven A. Shallcross CPA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 20 | Website https://therivabio.com |
Full time employees 20 | Website https://therivabio.com | ||
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. It has collaboration agreements with The University of Texas at Austin, Catalan Institute of Oncology, Fundació Privada Institut d'Investigacio Biomedica de Bellvitge, Saint Joan De Déu, and Massachusetts General Hospital, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.